272 related articles for article (PubMed ID: 26001052)
1. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib in ovarian cancer.
Khalique S; Banerjee S
Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.
Khosravi-Shahi P; Cabezon-Gutierrez L
Anticancer Agents Med Chem; 2012 Oct; 12(8):982-7. PubMed ID: 22263801
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G; Pectasides D
J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
[TBL] [Abstract][Full Text] [Related]
9. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic agents in ovarian cancer: past, present, and future.
Monk BJ; Minion LE; Coleman RL
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i33-i39. PubMed ID: 27141068
[TBL] [Abstract][Full Text] [Related]
11. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
12. Emerging growth factor receptor antagonists for ovarian cancer treatment.
Bonilla L; Oza A; Lheureux S
Expert Opin Emerg Drugs; 2018 Mar; 23(1):1-16. PubMed ID: 29528256
[TBL] [Abstract][Full Text] [Related]
13. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Klempner SJ; Myers AP; Mills GB; Westin SN
Expert Opin Pharmacother; 2013 Nov; 14(16):2171-82. PubMed ID: 23937415
[TBL] [Abstract][Full Text] [Related]
14. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL; Baggerly KA; Armaiz-Pena GN; Kang Y; Sanguino AM; Thanapprapasr D; Dalton HJ; Bottsford-Miller J; Zand B; Akbani R; Diao L; Nick AM; DeGeest K; Lopez-Berestein G; Coleman RL; Lutgendorf S; Sood AK
Cancer Biol Ther; 2014 Jul; 15(7):919-29. PubMed ID: 24755674
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
Wei XW; Zhang ZR; Wei YQ
Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
20. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
Secord AA; Nixon AB; Hurwitz HI
Gynecol Oncol; 2014 Nov; 135(2):349-58. PubMed ID: 25178997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]